ArticleInnovation (Cambridge (Mass.))2025
Artificial intelligence-curated repository of gene-encoded natural diverse components from herbal medicines.
Article in Innovation (Cambridge (Mass.)), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Multi-target cell membrane chromatography intelligent screening strategy and its application in drug discovery.Journal of pharmaceutical analysis · 2026Article
- Dual-driven by regulatory science and policy reconstruction: Traditional Chinese medicine (TCM) new drugs accelerate development-A critical review of highlights in registration and regulation of TCM and natural medicine new drugs in China (2021-2025).Acta pharmaceutica Sinica. B · 2026Article
- Engineering selective PI3KActa pharmaceutica Sinica. B · 2026Article
- Revolutionizing drug discovery from natural products: The roles of artificial intelligence and multi-omics in accelerating innovation.Acta pharmaceutica Sinica. B · 2026Article
- Innovative strategies for anti-fibrotic drugs discovery from traditional Chinese medicine.Chinese herbal medicines · 2026Review
- Comparative genomics reveals the evolution of anthraquinone biosynthesis in Polygonaceae.BMC genomics · 2026Article
- PhytosRNA therapeutics: Cross-kingdom communication and translational potential of Chinese herbal medicine-derived small RNAs.Plant cell reports · 2026Review
- Exploring the global mosaic of medicinal plant databases: unveiling nature's pharmacopoeia.Natural products and bioprospecting · 2026Review
- DeepICER: A deep learning framework for predicting compound-induced gene expression profiles.Acta pharmaceutica Sinica. B · 2026Article
- AlkaPlorer: A database-driven explorer for natural alkaloids and derivatives.Journal of integrative plant biology · 2026Article
- Biosynthesis of benzylisoquinoline alkaloids and its evolution in plants.Plant communications · 2026Review
- Discovery of Obacunone as a TGR5 Agonist fromInternational journal of molecular sciences · 2026Article
- Zebrafish as a translational platform for investigating multi-organ pharmacological interactions of traditional Chinese medicine.Frontiers in pharmacology · 2026Review
- Herbgenomics: Unraveling natural product biosynthesis in traditional Chinese medicine.Chinese herbal medicines · 2026Article
- Omics-based profiling and therapeutic potential of natural components in pan-Shennongjia medicinal herbs.Chinese medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural components, evolved to help organisms adapt and defend against threats, are also vital sources for drug discovery due to their diverse and potent bioactivities. In the present work, we proposed the Gene-encoded Natural Diverse Components Repository (GNDC, https://cbcb.cdutcm.edu.cn/gndc/), a primary and most extensive database dedicated to cataloging diverse natural components. GNDC currently catalogs over 234 million natural components that are organized into four specialized sub-databases: HerbalMDB for 2.32 million secondary metabolites, HerbalPDB for 229 million small peptides, HerbalRDB for 2.38 million small RNAs, and HerbalCDB for 0.26 million carbohydrates. By leveraging customized pipelines for high-throughput multi-omics data and AI technologies, the GNDC enables large-scale discovery and annotation of natural products from nuclear and organellar genomes of species listed in eight global pharmacopoeias and multi-resource data. Compared to existing resources, GNDC achieves a 10-fold increase in component yield and introduces over 200 million previously unreported components. To support this unprecedented data volume and complexity, state-of-the-art AI tools are seamlessly integrated to decipher and annotate vast data collections, such as classification and gene expression signature generation of millions of secondary metabolites. We envision that the GNDC will drive the transformation of drug discovery from an "experience-driven" approach to a "big data-driven" paradigm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.